Durvalumab in DLBCL After Autologous Transplant

Sponsor
Insel Gruppe AG, University Hospital Bern
Study ID
NCT03241017
Phase
PHASE2
Status
Withdrawn

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Immunotherapy with Durvalumab after ASCT

Study Details

The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.

Key Dates

First listed
Aug 7, 2017
Start date
Oct 31, 2017
Status verified
Apr 2018
Primary completion
Oct 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab
    Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).

Primary Outcome Measure

Progression-free survival [ Time Frame: 24 months ]

Related Studies